Effect of active vitamin D supplementation on muscle mass and function in peritoneal dialysis patients with sarcopenia: a randomized controlled trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This single-center, randomized, open-label, parallel-controlled clinical trial was conducted at the Ningbo No.2 Hospital, which serves as a tertiary care center in the Ningbo region of Zhejiang Province, China.

Participants were randomly allocated in a 1:1 ratio to either the intervention group (n = 25) or the control group (n = 25).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

ESRD patients with sarcopenia and vitamin D insufficiency or deficiency (serum 25(OH)D levels < 30 ng/mL) who were undergoing PD were recruited for the study.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are Sarcopenia, Peritoneal Dialysis, Vitamin D, Muscle, Skeletal, Dietary Supplements, Kidney Failure, Chronic and Vitamin D Deficiency.

Author keywords: Muscle function and Muscle mass.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2026 (Scientific reports), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.